Study S002243

Evaluation of the Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (CAMEO-SEMA)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Informed Consent Form (PDF)

Registration

Registration: NCT05371496
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: COMPLETED
Enrollment: 81
Start: 2022-09-06
Primary completion: 2026-07-17
Lead sponsor: Mayo Clinic
Conditions: Cardiomyopathy; Heart Failure With Preserved Ejection Fraction (HFpEF); Obesity
Interventions: DRUG:Semaglutide; DRUG:Placebo; BEHAVIORAL:Counselling on healthy lifestyle intervention
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Pulmonary Capillary Wedge Pressure (PCWP) [Baseline, 12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.